Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 30, 2026
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
Journal: Gynecologic oncology
Published: January 27, 2025
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
Journal: Cancer treatment reviews
Published: March 19, 2022
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 04, 2021
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 22, 2020
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.
Journal: JCO precision oncology
Published: June 23, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Journal: Nature reviews. Clinical oncology
Published: April 22, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 13, 2020
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 01, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases.
Journal: JCO precision oncology
Published: September 06, 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Journal: JCO precision oncology
Published: June 14, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 26, 2019
Last Updated: 09/26/2026